Pharmacogenomics and Personalized Medicine

1. Front Matter

   Pages i-xv

   PDF

2. Challenges, Opportunities, and Evolving Landscapes in Pharmacogenomics and Personalized Medicine

   • Nadine Cohen, Theresa Frangiosa

   Pages 1-26

3. Implementation of Pharmacogenomic Sample Collection in Clinical Trials

   • Deborah Sokol Ricci, Monique Franc

   Pages 27-54

4. Pharmacogenomics

   • Myong-Jin Kim, Shiew-Mei Huang, Atiqur Rahman, Felix W. Frueh, Lawrence J. Lesko

   Pages 55-71

5. Applications of Pharmacogenomics in Drug Discovery

   • McHale Duncan

   Pages 73-87

6. Applications of Pharmacogenomics in Clinical Trials

   • Monique Franc

   Pages 89-107

7. Pharmacogenomics Applications in Drug Metabolism

   • Ann K. Daly

   Pages 109-120

8. The Genetics of Adverse Drug Reactions

   • Martin Armstrong

   Pages 121-147

9. Strategies and Resources for Marker Selection and Genotyping in Genetic Association Studies

   • Nicole Soranzo, Fu Dong-Jing, S. Li Qingqin

   Pages 149-183

10. Study Design and Statistical Issues in Pharmacogenetics Research

    • Nicholas J. Schork, Nathalie Malo, Eric J. Topol

    Pages 185-206

11. Holy SNP, Batman!

    • Reyna Favis

    Pages 207-227

12. Predictive Biomarker Classifiers in the Design of Pivotal Clinical Trials

    • Richard Simon

    Pages 229-238

13. Translation of Biomarkers into Clinical Utility

    • William L. Trepicchio, George Mulligan

    Pages 239-251

14. Pharmacogenomic Study Feasibility Assessment and Pharmaceutical Business Decision-Making

    • Monique Franc, Theresa Frangiosa

    Pages 253-265

15. Co-Development of Drugs and Pharmacogenomics-Based Diagnostics in Oncology

    • Jeffrey S. Ross

    Pages 267-298

16. Pharmacogenomics Applications in Epilepsy Chantal Depondt

    • Chantal Depondt

    Pages 299-316

17. Pharmacogenomics in Alzheimer's Disease

    • Ramón Cacabelos

    Pages 317-368

18. Pharmacogenomics Applications in Psychiatric Disorders

    • Todd Lencz, Anil K. Malhotra

    Pages 369-394

19. Pharmacogenomics in HIV Disease

    • Amalio Telenti

    Pages 395-412

20. Pharmacogenomics and Cardiovascular Drugs

    • Gérard Siest, Hind Berrahmoune, Jean-Brice Marteau, Sophie Visvikis-Siest

    Pages 413-446

concerns within the pharmaceutical industry about generating data that might be difficult to interpret in a regulated environment. There is also a growing apprec- tion for the challenges in translating this new information into clinical utility, including scientific, commercial, ethical, and policy challenges. Pharmacogenomics and Personalized Medicine, which is part of the Methods in Pharmacology and Toxicology series, comprises chapters on selected aspects of pharmacogenomics and personalized medicine. Our overall intent is to assist both novice and experienced investigators in understanding the current scientific ch- lenges in applying PGx to discovery and clinical development and in making app- priate decisions to engage in and interpret PGx research. Designed to share the experiences of leading experts in the field, the book is a useful guide for conducting PGx research--from discovery to the market, but we also aim to present a realistic perspective on the challenges, practicalities, and obstacles in applying pharmac- enomics. Generally, the book avoids statements such as “Pharmacogenomics is going to revolutionize the practice of medicine,” which are neither realistic nor particularly useful to anyone. The book presents an industry perspective on the implementation of PGx in research and development, in drug discovery, and in clinical trials, including rec- mendations for a systematic approach for assessing the feasibility and added value of PGx studies in clinical trials.

• DNA
• DNA data
• Drug discovery
• Drug reactions
• Genetic research
• HIV
• PGx
• Pharmaceutical industry
• Research and development
• SNP
• genetics
• translation

From the reviews:

"The purpose is to provide a practical and integrative view of the application of pharmacogenomics to personalized medicine. … the information is valuable for scientists in academic, industrial, and healthcare areas who are striving to transform the current practice of medicine into personalized medicine. … this one provides the most comprehensive discussion on how to apply pharmacogenomics to attain greater success in bringing personalized medicine to clinical practice." (Xiaobo Zhong, Doody’s Review Service, January, 2009)

• Johnson and Johnson Pharmaceutical Research and Development, L.L.C., Raritan, USA

  Nadine Cohen

Policies and ethics